[go: up one dir, main page]

TNSN08194A1 - Compositions pharmaceutiques solides contenant de la pregabaline - Google Patents

Compositions pharmaceutiques solides contenant de la pregabaline

Info

Publication number
TNSN08194A1
TNSN08194A1 TNP2008000194A TNSN08194A TNSN08194A1 TN SN08194 A1 TNSN08194 A1 TN SN08194A1 TN P2008000194 A TNP2008000194 A TN P2008000194A TN SN08194 A TNSN08194 A TN SN08194A TN SN08194 A1 TNSN08194 A1 TN SN08194A1
Authority
TN
Tunisia
Prior art keywords
des
pharmaceutical compositions
compositions containing
solid pharmaceutical
gonflement
Prior art date
Application number
TNP2008000194A
Other languages
English (en)
Inventor
Howard Norman Bockbrader
Yun Hyung Cho
Santiago Steven Diaz
Majid Mahjour
Thomas Daniel Reynolds
Pushpa Ganapathi Shao
Zezhi Jesse Shao
Jiansheng Wan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN08194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN08194A1 publication Critical patent/TNSN08194A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une composition pharmaceutique solide contenant de la prégabaline est décrite. La composition comprend un agent de formation de matrice et un agent de gonflement et est apte à l'administration orale une fois par jour. Des exemples d'agents de formation de matrice comprennent des mélanges d'acétate de polyvinyle et de polyvinylpyrrolidone et des exemples d'agents de gonflement comprennent des polymères rétriculés de polyvinylpyrrolidone.
TNP2008000194A 2005-11-02 2008-04-30 Compositions pharmaceutiques solides contenant de la pregabaline TNSN08194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73258905P 2005-11-02 2005-11-02
PCT/IB2006/003063 WO2007052125A2 (fr) 2005-11-02 2006-10-23 Compositions pharmaceutiques solides contenant de la pregabaline

Publications (1)

Publication Number Publication Date
TNSN08194A1 true TNSN08194A1 (fr) 2009-10-30

Family

ID=37965070

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000194A TNSN08194A1 (fr) 2005-11-02 2008-04-30 Compositions pharmaceutiques solides contenant de la pregabaline

Country Status (33)

Country Link
US (11) US20070269511A1 (fr)
EP (1) EP1945186B1 (fr)
JP (1) JP4334610B2 (fr)
KR (1) KR101012533B1 (fr)
CN (1) CN101330907B (fr)
AP (1) AP2008004465A0 (fr)
AR (1) AR058175A1 (fr)
AU (1) AU2006310217B2 (fr)
BR (1) BRPI0618211B8 (fr)
CA (1) CA2628200C (fr)
CR (1) CR9950A (fr)
DK (1) DK1945186T3 (fr)
DO (1) DOP2006000241A (fr)
EA (1) EA012377B1 (fr)
EC (1) ECSP088422A (fr)
ES (1) ES2449231T3 (fr)
GT (1) GT200600474A (fr)
IL (1) IL190827A (fr)
MA (1) MA30135B1 (fr)
ME (1) ME00482B (fr)
NL (1) NL2000281C2 (fr)
NO (1) NO20081816L (fr)
NZ (1) NZ567414A (fr)
PE (1) PE20070693A1 (fr)
PL (1) PL1945186T3 (fr)
PT (1) PT1945186E (fr)
RS (1) RS20080181A (fr)
SI (1) SI1945186T1 (fr)
TN (1) TNSN08194A1 (fr)
TW (1) TWI330080B (fr)
UY (1) UY29890A1 (fr)
WO (1) WO2007052125A2 (fr)
ZA (1) ZA200803115B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200184T7 (es) 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
ATE542525T1 (de) * 2007-10-16 2012-02-15 Pharmathen Sa Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
CL2008003800A1 (es) * 2007-12-21 2010-01-22 Synthon Bv Sal de acido sulfonico de pregabalina, procedimiento de preparacion, composicion farmaceutica, util para tratar trastornos neuropsiquiatricos, esquizofrenia, epilepsia, fibromialgia, trastorno de ansiedad generalizada, trastorno de panico y fobia social y dolor por ejemplo dolor neuropatico.
BRPI0915508B1 (pt) * 2008-07-09 2019-11-19 Melaleuca Inc complexo de polissacarídeos de mineral-aminoácido, processo para preparar o referido complexo, e composição compreendendo dois ou mais dos referidos compostos
EP2440190A1 (fr) 2009-06-12 2012-04-18 Micro Labs Limited Nouvelles compositions pharmaceutiques contenant de la prégabaline
WO2010150221A1 (fr) 2009-06-25 2010-12-29 Wockhardt Research Centre Compositions pharmaceutiques de prégabaline de saveur masquée
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
NZ629036A (en) * 2010-02-24 2014-09-26 Zoetis Llc Veterinary compositions
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011124953A2 (fr) * 2010-04-07 2011-10-13 Lupin Limited Compositions pharmaceutiques à libération contrôlée de tapentadol
EP2389933A1 (fr) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions comprenant de la prégabaline à libération contrôlée
EP2389934A1 (fr) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prégabaline en comprimé à libération prolongée
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
IN2012MN02923A (fr) * 2010-06-01 2015-06-05 Rubicon Res Private Ltd
WO2012003968A1 (fr) * 2010-07-06 2012-01-12 Grünenthal GmbH Nouvelles formes posologiques à rétention gastrique comprenant un analogue de gaba et un opioïde
EP2415460A1 (fr) * 2010-08-03 2012-02-08 ratiopharm GmbH Formulations pour l'administration orale de prégabaline
EP2615913A4 (fr) * 2010-09-17 2014-03-19 Panacea Biotec Ltd Compositions pharmaceutiques à libération prolongée contenant de la prégabaline
CN103561727B (zh) 2010-12-02 2018-03-27 优时比制药有限公司 每日给药1次的拉科酰胺制剂
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
EP2736499B1 (fr) * 2011-07-26 2016-05-11 Yuhan Corporation Comprimé à libération continue comprenant de la prégabaline par un système de commande de libération à deux phases
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
EP2809303A1 (fr) * 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Comprimés de prégabaline gastro-résistants
EP2809304A1 (fr) 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Comprimés gastro-résistants
CN102743357A (zh) * 2012-06-26 2012-10-24 严轶东 一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
WO2014060952A1 (fr) 2012-10-16 2014-04-24 Ranbaxy Laboratories Limited Comprimés osmotiques flottants
IN2014MU00198A (fr) * 2014-01-21 2015-08-28 Intas Pharmaceuticals Ltd
EP3099288A1 (fr) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Comprimés à rétention gastrique stabilisée de prégabaline
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2016062182A1 (fr) * 2014-10-24 2016-04-28 江苏恒瑞医药股份有限公司 Préparation à libération prolongée de prégabaline
CN104906064B (zh) * 2015-05-15 2017-12-22 中国药科大学 一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) * 2015-05-20 2017-08-29 Altera Corporation Pipelined cascaded digital signal processing structures and methods
EP3302425A4 (fr) * 2015-05-26 2018-12-26 Isa Odidi Prégabaline à libération prolongée contrôlée
CN104840443B (zh) * 2015-05-27 2018-04-27 齐鲁制药有限公司 含活性成分普瑞巴林的药物组合物
WO2017058869A1 (fr) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Compositions à libération prolongée de 4-aminopyridine
BR112019000636A2 (pt) * 2016-07-17 2019-04-30 Mapi Pharma Ltd. formas de dosagem de liberação prolongada de pregabalina
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
WO2019146642A1 (fr) * 2018-01-24 2019-08-01 大原薬品工業株式会社 MÉTHODE D'AMÉLIORATION DE LA STABILITÉ CHIMIQUE D'UN COMPRIMÉ CONTENANT UN DÉRIVÉ D'ACIDE γ-AMINOBUTYRIQUE
CN110294684A (zh) * 2018-03-22 2019-10-01 日东电工株式会社 含有普瑞巴林的组合物的制造方法以及含有普瑞巴林的组合物
CN110585153A (zh) * 2018-06-13 2019-12-20 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111741748B (zh) * 2018-06-13 2022-09-23 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CA3105212A1 (fr) * 2018-06-28 2020-01-02 Mylan Inc. Formulations a liberation prolongee de pregabaline
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
DK3760190T3 (da) 2019-07-03 2023-09-04 Alvogen Inc Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
US12012413B2 (en) * 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
EP4309648A4 (fr) * 2021-03-17 2025-03-05 Shanghai Yonsun Biotechnology Co., Ltd. Composition pharmaceutique de lacosamide, son procédé de préparation et ses applications
CN113577036B (zh) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) * 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483751D1 (de) 1983-05-02 1991-01-31 Diamond Scient Co Photochemische entkeimungsbehandlung von vollem blut oder blutbestandteilen.
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
IN186245B (fr) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
KR100602047B1 (ko) 1998-05-15 2006-07-19 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체의 안정화된 제약 제제 및그의 제조 방법
BR9910494B1 (pt) 1998-05-15 2011-11-01 composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo.
PT1250311E (pt) * 2000-01-27 2004-07-30 Warner Lambert Co Sintese assimetrica de pregabalina
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
ATE255891T1 (de) 2000-06-16 2003-12-15 Teva Pharma Stabiles gabapentin, das mehr als 20 ppm chlor enthält
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
EP1305021A4 (fr) 2000-06-23 2009-09-23 Teva Pharma Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
CA2356829A1 (fr) * 2000-09-22 2002-03-22 Warner-Lambert Company Methode de traitement de l'asthme avec la pregabaline
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
WO2005025562A1 (fr) * 2003-09-11 2005-03-24 Xenoport, Inc. Traitement et/ou prevention de l'incontinence urinaire et promedicaments des analogues gaba
JP2007509976A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増加された鉄の吸収のための組成物及び投与形態

Also Published As

Publication number Publication date
US10022447B2 (en) 2018-07-17
ECSP088422A (es) 2008-05-30
US20070269511A1 (en) 2007-11-22
EP1945186A2 (fr) 2008-07-23
EA200800931A1 (ru) 2008-10-30
NL2000281A1 (nl) 2007-05-03
CN101330907A (zh) 2008-12-24
US9144559B2 (en) 2015-09-29
US20150352066A1 (en) 2015-12-10
TW200803831A (en) 2008-01-16
US20160250147A1 (en) 2016-09-01
SI1945186T1 (sl) 2014-03-31
BRPI0618211A2 (pt) 2011-08-23
JP4334610B2 (ja) 2009-09-30
US20120232149A1 (en) 2012-09-13
US20170348420A1 (en) 2017-12-07
CA2628200A1 (fr) 2007-05-10
US20130303618A1 (en) 2013-11-14
IL190827A0 (en) 2008-12-29
PL1945186T3 (pl) 2014-05-30
EP1945186B1 (fr) 2014-01-22
UY29890A1 (es) 2007-05-31
US20170136125A1 (en) 2017-05-18
ME00482B (fr) 2011-10-10
AU2006310217B2 (en) 2012-08-16
BRPI0618211B8 (pt) 2021-05-25
CN101330907B (zh) 2012-08-29
BRPI0618211B1 (pt) 2020-11-17
EA012377B1 (ru) 2009-10-30
KR101012533B1 (ko) 2011-02-07
NZ567414A (en) 2011-09-30
MA30135B1 (fr) 2009-01-02
IL190827A (en) 2012-08-30
DOP2006000241A (es) 2007-05-31
ZA200803115B (en) 2009-09-30
RS20080181A (en) 2009-07-15
AP2008004465A0 (en) 2008-06-30
PT1945186E (pt) 2014-03-06
US20140163103A1 (en) 2014-06-12
NO20081816L (no) 2008-05-08
US20120029081A1 (en) 2012-02-02
US8945620B2 (en) 2015-02-03
CR9950A (es) 2008-05-28
AR058175A1 (es) 2008-01-23
HK1126394A1 (en) 2009-09-04
GT200600474A (es) 2007-06-08
TWI330080B (en) 2010-09-11
PE20070693A1 (es) 2007-08-11
ES2449231T3 (es) 2014-03-18
US20130102675A1 (en) 2013-04-25
DK1945186T3 (en) 2014-03-17
JP2009514847A (ja) 2009-04-09
AU2006310217A1 (en) 2007-05-10
WO2007052125A2 (fr) 2007-05-10
NL2000281C2 (nl) 2007-08-07
CA2628200C (fr) 2011-01-25
KR20080059427A (ko) 2008-06-27
WO2007052125A3 (fr) 2007-09-07
US20150094371A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
TNSN08194A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
MA28140A1 (fr) Compositions et formes dosifiees pour favoriser l'absorption de la gabapentine et de la pregabaline
MA34474B1 (fr) Agonistes de gpr40
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
CY1105559T1 (el) Φαρμακευτικες συνθεσεις του tegaserod
MA31894B1 (fr) Composes organiques
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN07423A1 (fr) Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol, le borneol, le carvacrol, l 'alpha-ionone ou le beta-ionone
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
MA29775B1 (fr) Derives de pyrazolone
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.